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CDSolid and gaseous cerebral microembolization after
biologic and mechanical aortic valve replacement:
Investigation with multirange and multifrequency
transcranial Doppler ultrasound
Lorenzo Guerrieri Wolf, MD, Bikram P. Choudhary, MRCS, Yasir Abu-Omar, MRCS, and
David P. Taggart, MD (Hons), PhD, FRCS
Objective: Cerebral microembolization is a well-recognized phenomenon after
cardiac valve replacement, but the relative proportion of solid and gaseous
emboli is uncertain. Particulate microemboli are thought to be the most dam-
aging. With the use of multifrequency transcranial Doppler ultrasound, we
compared the number and nature of microemboli in recipients of biologic and
mechanical aortic valve prostheses.
Methods: The middle cerebral arteries of 60 patients were monitored bilaterally with
a new-generation transcranial Doppler ultrasound (Embo-Dop, DWL Elektronische
Systeme GmbH, Singen, Germany) that rejects artefacts online and automatically
discriminates between solid and gaseous microemboli. All recordings were per-
formed during a 30-minute period 1 day before and at a mean of 5 days and 3
months after isolated aortic valve replacement with a biologic (30, group B) or
mechanical (30, group M) prosthesis.
Results: The patients in group B were older, with a mean age of 70.6  9.7 years
versus 55.4  9.4 years (P  .005) in the patients in group M. Biologic
prosthesis recipients were all taking aspirin (no warfarin); patients with me-
chanical valves were well anticoagulated with warfarin both 5 days and 3
months after surgery. None of the patients had solid microemboli preoperatively.
Five days postoperatively, the absolute number of cerebral microemboli was 145
and 594 for total microemboli (P  .001) and 41 and 182 for solid microemboli
(P  .002) in groups B and M, respectively. At 3 months, the absolute number
was 65 and 608 for total microemboli (P  .001) and 10 and 188 for solid
microemboli (P  .001) in groups B and M, respectively. Solid microemboli
accounted for 16% of the total microembolic load in group B compared with
31% in group M (P  .05) at 3 months.
Conclusions: Solid cerebral microemboli represent approximately one third of
the total cerebral microembolic load after mechanical aortic valve replacement
and are detectable in the majority of such patients both 5 days and 3 months after
surgery. The neurofunctional consequences of this phenomenon should be
carefully assessed.
Since the first detection of intracavitary echoes in prosthetic heart valves in1975,1 several studies have reported transcranially detected high intensitytransient signals (HITS) in patients with a normally functioning heart valve
prosthesis, including mechanical,2-9 bioprosthetic,6,7,10 homograft,11 and pulmonary
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autograft recipients, implying cerebral microembolization.
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CDIntraoperative cerebral microembolization is considered
to be an important cause of postoperative neurocognitive
decline in cardiac surgery.13-16 This finding is supported by
our own recent demonstration of a correlation between the
number of intraoperative cerebral microemboli and the sub-
sequent impairment of verbal memory defined by functional
magnetic resonance imaging of the brain in patients under-
going coronary artery bypass grafting.17,18 Although there is
previous2,19 and more recent9 evidence that a higher HITS
count is associated with worse neuropsychologic outcome,
there is also evidence that HITS after valve replacement
have no correlation with neuropsychologic outcome.6,20-22
Consequently, any postulated correlation between neuro-
cognitive damage and ongoing postoperative cerebral mi-
croemboli production in heart valve prosthesis recipients
must be regarded as controversial.
Microembolization after valve replacement is a multifac-
torial and complex process. It is thought to be caused mainly
by high hemodynamic stresses at the valvular level22 as a
consequence of high energy dissipation at valve closure23
and extremely low pressure zones on the inflow side of
mechanical heart valves.24 This is exaggerated by turbulent
blood flow downstream from prosthetic valves22,24 leading
to the formation of nitrogen and oxygen gas bubbles and/or
thrombocyte aggregates, which are subsequently recorded
in the cerebral circulation as HITS. Prosthetic valve de-
sign6,24-26 and orientation26 influence both shear rates and
the grade of blood flow turbulence and are thought to have
an important impact on the formation of such microemboli.
Other factors (patient’s age,22 myocardial contractility,27
heart rate,27 method of valve implantation,28 valve dys-
function,29 acetylsalicylate infusion,3,24 oxygen ther-
apy,5,7,21,24,30 hyperbaric oxygen8) have also been found to
influence HITS rate after prosthetic valves replacement.
The composition of cerebral microemboli in recipients of
prosthetic valves has previously been suspected from vari-
ous indirect evidence (O2, hyperbaric O2, antiplatelet
agents). Although particulate microemboli are likely to be
more damaging than gaseous microemboli, a closer corre-
lation between solid cerebral microembolization and neuro-
cognitive decline might be anticipated. Several articles31,32
have also dealt with the issue of the potential damaging
effects of gaseous microemboli.
In the present study, a new-generation transcranial Dopp-
ler (TCD) ultrasound33,34 that rejects artefacts online and
Abbreviations and Acronyms
AVR  aortic valve replacement
HITS high intensity transient signals
MCAmiddle cerebral artery
TCD  transcranial DopplerThe Journal of Thoracautomatically discriminates between solid and gaseous mi-
croemboli was used to compare the number and nature of
microemboli in patients with biological and mechanical
aortic valve prostheses early and late after operation in an
attempt to determine the exact proportion of particulate
microemboli.
Materials and Methods
A total of 60 patients admitted to the John Radcliffe Hos-
pital for elective isolated aortic valve replacement (AVR)
were prospectively recruited for the study. All patients gave
informed consent, and full ethical approval was obtained
from the local research ethics committee (Oxford Research
Ethics Committee number C01.258).
The patients were divided into 2 groups. Thirty patients
underwent isolated AVR with biological prostheses (group
B), and 30 patients underwent isolated AVR with mechan-
ical prostheses (group M). Patients with symptomatic ca-
rotid disease, peripheral vascular disease, preoperative neu-
rologic history, or atrial fibrillation were excluded. Methods
of valve implantation included the interrupted suture tech-
nique with positioning of subannular pledgets and the con-
tinuous suture technique with six 2-0 polypropylene sutures.
Methods of myocardial protection, cardiopulmonary by-
pass, aortotomy, valve excision, and debridement were sim-
ilar in all of the study patients. Transesophageal echocardi-
ography was used routinely in all study patients to
demonstrate normal function and seating of the valve and to
confirm adequate deairing. All mechanical valves were im-
planted in their optimum orientation.35 All patients had a
well-functioning aortic prosthesis as demonstrated by echo-
cardiography at the times when the TCD studies were
conducted. By the fourth postoperative day, none of the
patients were receiving supplemental oxygen.
Transcranial Doppler Monitoring
Bilateral TCD monitoring of the middle cerebral arteries for
a continuous period of 30 minutes was performed in all
patients 1 day before the operation and at a mean of 5 days
(5  1 days in group B and 5.5  1.3 days in group M) and
3 months (90  14 days in group B and 90  7 days in
group M) after surgery.
All recordings of the middle cerebral artery (MCA) were
performed bilaterally using a multirange, multifrequency
TCD (Embo-Dop; DWL Elektronische Systeme GmbH,
Singen, Germany), which rejects artefacts online and auto-
matically discriminates between solid and gaseous micro-
emboli.33,34 We previously described this new-generation
equipment.17 In brief, we simultaneously insonated the
MCAs bilaterally through dual-frequency probes (2.0 and
2.5 MHz) fixed to the transtemporal windows above the
right and left zygomatic arches using a specifically designedic and Cardiovascular Surgery ● Volume 135, Number 3 513
)an
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CDgate was set 15 mm superficially to the MCA insonation
gate whose depth was set between 45 and 55 mm with a
sample volume of 13 mm. The multifrequency system (2.0
MHz and 2.5 MHz) serves for the automatic microemboli
nature discrimination: Gaseous microemboli reflect more
ultrasound at lower frequencies than at higher frequencies,
contrary to what occurs in the case of solid microemboli.
The reference gate serves for the online rejection of arti-
facts: The latter are identified when HITS are detected in
both gates (MCAs and reference gates) simultaneously or
with a time delay of less than 4 msec.
Statistical Analysis
Patient characteristics are presented as mean  standard
deviation or percentage of the total. The number of micro-
emboli is presented as the absolute number and the median
and 25th to 75th percentiles. Statistical comparison, for
normally distributed data, was performed using the Student
t test for continuous variables and the chi-square test or
Fisher exact test (as appropriate) for categoric variables.
Because the data for the number of microemboli were not
normally distributed, the nonparametric Mann–Whitney U
test was used to compare the difference among the 2 groups.
The Wilcoxon test was used to analyze the variation of the
number of microemboli over time within each group. A
stepwise logistic regression analysis was performed to se-
lect predictors of HITS; the model was built using variables
that demonstrated a P value less than .10 in the univariate
analysis. The significance within the model was evaluated
with the Wald statistical test. The Statistical Package for the
Social Sciences version 12.0 (SPSS Inc, Chicago, Ill) soft-
ware was used for statistical calculations.
Results
Patients in group B (22 male, 8 female) were older than
those in group M (23 male, 7 female), with a mean age of
70.6  9.7 years versus 55.4  9.4 years (P  .005). All
other demographic and preoperative patient characteristics
were similar in the 2 groups and are summarized in Tabl
Operative and postoperative data are shown in Table 
Biological prosthesis recipients all received aspirin (no war-
farin); patients with mechanical valves all received oral
anticoagulants with a mean international normalized ratio in
the therapeutic range (2.8  0.6) both 5 days and 3 months
after surgery. The types of valve prostheses implanted in the
study patients are summarized in Table 3.
Microemboli
Twenty percent of patients in both groups were positive for
HITS before the operation, but none were solid microem-
boli. The relative frequency of patients positive for HITS
was significantly higher in mechanical heart valve prosthe-
sis recipients than in biological recipients both 5 days and 3514 The Journal of Thoracic and Cardiovascular Surgery ● Mae 1.
2.
months after surgery. An even more marked difference
between the 2 groups was evident for solid microemboli.
The percentage of bioprostheses recipients who were posi-
tive for solid microemboli decreased significantly over time
(P  .01), but this did not occur in those with mechanical
valves (Table 4).
A similar small amount of total microemboli were de-
tected in biological and mechanical aortic valve prostheses
recipients before the operation. At 5 days and 3 months after
surgery the median number (25th–75th percentile) of any
microemboli (Figure 1) and solid microemboli (Figure 2
was significantly higher in mechanical recipients than bio-
logical recipients. Figures 1 and 2 show that the medi
number (25th–75th percentile) of any and solid microem-
boli decreased significantly over time in biological recipi-
ents, with a steady production of HITS in patients with
mechanical valves. Although a similar proportion of solid
microemboli was found between the 2 groups early postop-
eratively, at 3 months after surgery the proportion of par-
ticulate microemboli was significantly higher in group M
than in group B (Table 4).
In the multivariate analysis, increased heart rate and the
implantation of mechanical valve prosthesis were signifi-
TABLE 1. Demographic and preoperative patient charac-
teristics
Characteristics Group B Group M P value
No. 30 30 —
Age, y (mean  SD) 70.6  9.7 55.4  9.4 .005
Females, n (%) 8 (27) 7 (23) .76
Parsonnet score (mean
 SD)
7.9  7 8.5  6.6 .71
EURO score (mean 
SD)
3.4  2.1 3.4  2.4 .96
EF, % (mean  SD) 52.7  8 54  7 .73
Diabetes, n (%) 3 (10) 1 (3) .3
Hypertension, n (%) 19 (63) 15 (50) .29
Smoking, n (%) 19 (63) 16 (53) .43
Previous MI, n (%) 0 (0) 0 (0) —
Previous CVA/TIA, n
(%)
0 (0) 0 (0) —
PVD, n (%) 0 (0) 0 (0) —
AF, n (%) 0 (0) 0 (0) —
AS, n (%) 19 (63) 21 (70) .58
AR, n (%) 4 (13) 4 (13) 1
AS/AR, n (%) 7 (24) 5 (17) .51
Degenerative, n (%) 20 (67) 15 (50) .19
Congenital,* n (%) 8 (27) 11 (37) .4
Endocarditis,† n (%) 2 (6) 4 (13) .38
Rheumatic, n (%) 0 (0) 0 (0) —
SD, Standard deviation; EF, ejection fraction; MI, myocardial infarction;
CVA/TIA, cerebrovascular accident/transient ischemic attack; PVD, pe-
ripheral vascular disease; AF, atrial fibrillation; AS, aortic stenosis; AR,
aortic regurgitation; AS/AR, mixed pathology (stenosis plus regurgitation).
*Bicuspid valve. †Sequelae of healed infective endocarditis.rch 2008
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CDcantly associated with an increased number of HITS (P 
.02 and P  .003, respectively). We did not find an asso-
ciation with patient age.
Discussion
To our knowledge, this is the first report to use a multifre-
quency TCD to directly compare the number and nature of
cerebral microemboli in such a large cohort of biologic and
mechanical aortic valve prostheses recipients. The main
finding of this study was that solid microemboli represented
approximately one third of the total cerebral microembolic
load after mechanical AVR and were detectable in the
majority of such patients both 5 days (80%) and 3 months
(93%) after surgery. In addition, the present study demon-
strated that gaseous but not solid microemboli were detect-
able in approximately 20% of patients with aortic valvular
disease before surgery, presumably because of the turbu-
lence generated by a severely diseased valve, and that
microembolic signals occur in most patients after both me-
chanical and biologic valve replacement in the early post-
operative period. However, 3 months after surgery there
was a reduction in the number of HITS in bioprosthesis
recipients but a constant number in patients with a mechan-
ical prosthesis. Moreover, although a minority of patients
with bioprostheses experienced solid cerebral microembo-
lization both 5 days and 3 months after surgery, the propor-
tion of these patients who were positive for solid microem-
boli decreased over time. Finally, in accordance with
previous observations,5,8,36-39 we found that the majority o
TABLE 2. Operative and postoperative data
Data Group B Group M P value
CPB time, min (mean  SD) 74.1  6 73.8  5.8 .84
Crossclamp time, min (mean
 SD)
61.3 6.3 61.2  6 .94
Method of valve implantation
Subannular pledgets, n (%) 22 (73) 25 (83) .34
Continuous suture, n (%) 8 (27) 5 (17) .34
Valve size, mm (mean  SD) 23.1  1.9 23.8  2.2 .17
Valve type
Bileaflet, n (%) — 30 (100) —
Tilting disc, n (%) — 0 (0) —
Early-late postoperative EF
Good, n (%) 16 (54) 17 (57) .79
Fair, n (%) 10 (33) 9 (30) .78
Poor, n (%) 4 (13) 4 (13) 1
Early postoperative HR,
(mean  SD)
73.3 12 74  12.5 .82
Late postoperative HR,
(mean  SD)
73.5 12 74  12 .82
Early-late -blockade, n (%) 6 (20) 8 (27) .54
CPB, Cardiopulmonary bypass; SD, standard deviation; EF, ejection fraction
(good  50%, fair  40% 50%, poor 40%); HR, heart rate.The Journal of Thoraf
microemboli were gaseous in nature, with solid microem-
boli accounting for a percentage of total microembolic load
ranging between 16% (in biological prosthesis recipients, 3
months after surgery) and 31% (in mechanical prosthesis
recipients, both 5 days and 3 months after surgery).
Discrimination between solid and gaseous microemboli
in patients with prosthetic heart valves may have important
pathophysiologic, therapeutic, and prognostic implications.
The likely nature of cerebral microemboli in such patients
has been investigated in the past with differing methods
(Table 5). By performing simultaneous ultrasound monitor-
ing, Georgiadis and colleagues36 reported a significantly
higher number of HITS in the common carotid artery com-
pared with those of the ipsilateral middle and anterior ce-
rebral arteries in patients with artificial heart valves, arguing
that as bubbles implode with time, the majority of the HITS
were likely to be explained by gaseous emboli, consistent
with previous spectral characteristic analysis of HITS.39 A
similar conclusion was reached by Baumgartner and col-
leagues8 after demonstrating an increase in HITS in 15
mechanical valve recipients subjected to an increase in their
environmental pressure. On the other hand, others3,24,40-42
have provided plausible evidence about the likely solid
nature of at least some microemboli. Geiser and col-
leagues,41 using morphologic and functional methods, in-
cluding flow cytometry and platelet-specific antibodies, re-
ported an increased microembolic load and the presence of
TABLE 3. Type of valve prosthesis implanted in the study
patients
Group Prosthesis Patients (n)
M ATS (ATS Medical Inc, Minneapolis,
Minn)
17
MIRA (Edwards Lifesciences, Irvine,
Calif)
7
CarboMedics standard
(CarboMedics Inc, Austin, Tex)
2
CarboMedics Top Hat (CarboMedics
Inc)
2
St Jude Medical standard (St Jude
Medical Inc, St Paul, Minn)
2
B EL standard (Edwards Lifesciences,
Irvine, Calif)
13
Mosaic (Medtronic Inc.,
Minneapolis, Minn)
7
Aspire aortic (NoraMedica,
Copenhagen, Denmark)
3
EL Perimount (Edwards Lifesciences,
Irvine, Calif)
1
Mitroflow (CarboMedics Inc., Austin,
Tex)
5
3F (stentless) (3F Therapeutics, Lake
Forest, Calif)
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CDTABLE 4. Percentage of patients positive for any and solid microemboli, absolute number of any microemboli, and
proportion of solid and gaseous microemboli detected 1 day before and 5 days and 3 months after isolated aortic valve
replacement
Time at recording Group
Total patients Microemboli
With any microemboli
n (%)
With solid microemboli
n (%)
Any
n Gaseous n (%) Solid n (%)
Preoperatively B 6 (20) 0 (0) 26 26 (100) 0 (0)
M 6 (20) 0 (0) 15 15 (100) 0 (0)
5 d postoperatively* B 21 (70) 12 (40)‡ 145 104 (72) 41 (28)
M 29 (97) 24 (80) 594 412 (69) 182 (31)
3 mo postoperatively† B 18 (60) 4 (13)‡ 65 55 (84) 10 (16)
M 29 (97) 28 (93) 608 420 (69) 188 (31)
*Comparison between the 2 groups of 1) percentage of patients positive for microemboli: P  .005 (for any microemboli), P  .001 (for solid microemboli);
2) absolute number of microemboli: P  .001 (for any microemboli), P  .002 (for solid microemboli); and 3) proportion of solid and gaseous microemboli:
P  NS. †Comparison between the 2 groups of 1) percentage of patients positive for microemboli: P  .0005 (for any microemboli), P  .0001 (for solid
microemboli); 2) absolute number of microemboli: P  .001 (both for any and solid microemboli), and 3) proportion of solid and gaseous microemboli: P
 .05. ‡Comparison of percentage of bioprosthesis recipients positive for solid microemboli over time: P  .01.bplatelet microparticles associated with a procoagulant activ-
ity in patients with prosthetic heart valves symptomatic for
cerebrovascular events. Three years earlier, by monitoring
antithrombotic treatments and coagulation markers, the
same group42 showed that microemboli are likely to 
composed at least in part of platelets. Several other studies
supported this hypothesis by demonstrating a decrease in
Figure 1. Median number (25th–75th percentile) of total microem-
boli in biologic (group B) and mechanical (group M) aortic valve
prostheses recipients, as detected 1 day before (1) and 5 days
(5) and 3 months (90) after isolated AVR. Comparison of number of
total microemboli detected in group B: *1 day before and 5 days
after surgery (P  .001); †1 day before and 3 months after surgery
(P  .01); ‡5 days and 3 months after surgery (P  .04). Compar-
ison of number of total microemboli detected in group M: §1 day
before and 5 days after surgery (P < .0001); 1 day before and 3
months after surgery (P < .0002); #5 days and 3 months after
surgery (P  .5). NS, Not significant.
516 The Journal of Thoracic and Cardiovascular Surgery ● Me
HITS after oral3 or intravenous3,24 administration of anti-
platelet drugs. For example, Laas and colleagues24 found a
16% to 41% reduction with intravenously administered
lysine acetylsalicylate. suggesting that particulate microem-
boli constituted a minority component. However, the most
frequent method for demonstrating the likely gaseous nature
of the majority of cerebral microemboli in prosthetic valve
Figure 2. Median number (25th–75th percentile) of solid micro-
emboli in biologic (group B) and mechanical (group M) aortic
valve prostheses recipients, as detected 1 day before (1) and 5
days (5) and 3 months (90) after isolated AVR. Comparison of
number of solid microemboli detected in group B: *1 day before
and 5 days after surgery (P  .002); †1 day before and 3 months
after surgery (P  .06); ‡5 days and 3 months after surgery (P 
.02). Comparison of number of solid microemboli detected in
group M: §1 day before and 5 days after surgery (P< .0002); 1 day
before and 3 months after surgery (P < .0003); #5 days and 3
months after surgery (P  .6). NS Not significant.
arch 2008
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CDTABLE 5. Variation in transcranially detected cerebral microembolic load and microemboli nature discrimination methods
among different studies
First author
No. of patients (prosthesis type,
position)
Time at recording
postoperatively
(recording duration) HITS count/incidence†
Methods for microemboli
nature discrimination
Muller3 (1994) 100 (mechanical; A/M/AM) 3 wk (50 patients)
12 wk (50 patients)
(10 min)
-/54% (total)
-/66% (3 wk)
-/42% (12 wk)
Oral/IV antiplatelet
administration (7
patients)
Braekken4 (1995) 92 (mechanical; A) Early (36 patients)
12 mo (34 patients)
60 mo (22 patients)
(30 min)
-/87% (total)
-/77.8% (early)
-/91.2% (12 mo)
-/95.5% (60 mo)
—
Georgiadis5 (1997) 123 (mechanical; A/M/AM) 17  1* mo
(45 min)
-/48% 100% oxygen inhalation
(43 patients)
Sliwka6 (1998) 580 (mechanical/biological;
A/M/AM)
15  1* mo
(30 min)
4.5 (4 – 6)‡/65% (total)
0 (0 –1)‡/26% (biological)
6 (5–7.5)‡/70% (mechanical)
—
Milano7 (1999) 83 (mechanical/biological/
homograft/mitral repair;
A/M/AM)
Discharge/3 mo/12 mo
(30 min)
55  79§/30% (total)
-/85% (mechanical)
-/10% (biological)
-/0% (homograft/mitral repair)
100% oxygen inhalation
(12 patients)
Baumgartner8
(2001)
15 (mechanical; A/M/AM) NA
(30 min)
20 (12–78)‡ Hyperbaric exposure
Uekermann9
(2005)
40 (mechanical; A) 5.3* y (30 min) 42–531# (HITS-high group, 21
patients)
0 –30# (HITS-low group, 19
patients)
—
Grosset10 (1994) 64 (mechanical/biological;
A/M/AM)
NA -/72% (total)
-/88% (mechanical)
-/14% (biological)
—
Lievense11 (1998) 40 (mechanical/homograft; A) Outdoor patients
(30 min)
-/60% (total)
13 (0 –70)/80% (mechanical)
3 (0 –18)/40% (homograft)
—
Notzold12 (1997) 17 (mechanical/pulmonary
autograft; A)
NA
(60 min, unilateral)
2– 84#/100% (mechanical)
12**/25% (pulmonary
autograft)
—
Kaps21 (1997) 5 (mechanical; A) 8 mo 60 mo
(30 min)
9(2–55) 100% oxygen inhalation
Kofidis22 (2002) 42 (mechanical; A) NA
(60 min)
-/69% —
Laas24 (2003) 30 (bileaflet prosthesis/tilting
disc prosthesis; A)
9 mo
(30 min)
32–108# (bileaflet prosthesis)
0 –2# (tilting disc prosthesis)
100% oxygen inhalation/IV
antiplatelet
administration (10
patients)
Russell34 (2002) 15 (mechanical; NA) NA
(60 min)
514** Multifrequency TCD
6 (5–7.5)‡/70% (mechanical)
Systeme GmbH, Singen,
Germany)
Georgiadis36
(1998)
10 (mechanical; A/M/AM) 18 2* mo
(30 min)
112 (75–175)‡, CCA
30 (18 –36)‡, M/ACA
HITS counts decline from
CCA to M/ACA
Georgiadis39
(1994)
60 (mechanical; NA) 21  5* mo
(30 min)
5958** Spectral analysis of emboli
signals
Geiser41 (1998) 26 (mechanical; NA) 5.2  4.6* y (30 min) 24 (0–248)/81% Flow cytometry with
platelet-specific
antibodies
HITS, High intensity transient signal; A, aortic position; M, mitral position; AM, both aortic and mitral positions; NA, not available; CCA, common carotid
artery; M/ACA, middle/anterior cerebral artery; IV, intravenous. *Mean  standard deviation. †Percentage of patients positive for HITS. ‡Median (95%
confidence intervals). §Mean  standard deviation of HITS per hour. Median (range). #Range of HITS per hour. **Absolute number of HITS.
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CDrecipients was the reduction in HITS counts during 100%
oxygen inhalation:5,7,21,24,30 Milano and colleagues7 found a
decrease in the number of HITS per hour from 55 (79) to
22 (31) after 100% oxygen; Droste and colleagues30
found a decrease in HITS in 20 patients with mechanical
prosthetic cardiac valves from 144 HITS per hour without
oxygen to 63 HITS per hour with oxygen. These studies
actually suggested that approximately one third of the mi-
croemboli cannot be eliminated by 100% oxygen therapy
and thus may be particulate. Our results are in agreement
with these findings, and the comparison strengthens the
importance of their results.
Because only indirect methods have been used in the
literature to suggest that the nature of microemboli associ-
ated with valve prostheses may have a mixed composition,
we believe our study to determine the exact proportion of
solid and gaseous microemboli using a sophisticated new-
generation TCD is particularly valuable. As summarized in
Table 5, it can be seen that our results are broadly in
with the findings of previous studies6,7,10-12 in terms of the
incidence of HITS with mechanical valves. However, an
interesting finding is that we also found a far higher inci-
dence of HITS in biological valves. This could be the result
of an increased sensitivity or a decreased specificity of the
technique used for the microemboli detection. Indeed, the
automatic rejection of artifacts achievable with the Embo-
Dop system reduces bias in the interpretation of HITS and
avoids interobserver variability. The original “in vivo” val-
idation of the current multirange and multifrequency TCD
system was carried out by Russell and Brucher34 in a much
smaller cohort of prosthetic heart valve recipients. The
authors did not, however, compare mechanical and biolog-
ical prostheses. More recently, Markus and Punter,43 while
confirming the superior discrimination achievable with this
new Embo-Dop TCD system compared with conventional
TCD ultrasound, reported it to have a sensitivity of only
50% but a specificity of 96% for detecting solid microem-
boli in vivo. If confirmed, that finding will only serve to
emphasize the already significantly greater solid microem-
bolic load detected with mechanical rather than biological
prostheses.43 The suggestion that embolus detection an
differentiation may be unreliable in situations with bursts of
microemboli entering the sample volume at the same tim44
is not likely to influence our current observations because
the frequency of emboli generation was low. Finally, when
all the technical parameters of the system (ie, Doppler signal
enhancement) are satisfied, as in the current study, the
dual-frequency Doppler can discriminate the nature of mi-
croemboli with reliable results.44
Although biological recipients were all receiving aspirin,
mechanical recipients received warfarin without any anti-
platelet agents. This could explain the reduction in the
proportion of particulate microemboli over time in the bio-518 The Journal of Thoracic and Cardiovascular Surgery ● Maline
logical valve group but not in the mechanical group. Be-
cause the use of aspirin in addition to warfarin after me-
chanical valve replacement has been convincingly shown to
reduce the incidence of thromboembolic events and death
(the benefit was greater than the increased risk of bleed-
ing),45,46 it would be interesting to examine HITS using
aspirin as well as warfarin in the mechanical valve
recipients.
It is tempting to speculate that the steady production of
solid microemboli detected in mechanical prosthesis recip-
ients during a 30-minute period, if extrapolated over many
years, could clarify at least in part the pathologic mecha-
nisms causing neurocognitive decline associated with
chronic cerebral microembolisation in some studies,2,9,19
but other studies have found no such relationship.6,20-22
Zimpfer and colleagues47 initially reported immediate post-
operative impairment of neuropsychologic outcome in pa-
tients with mechanical and biologic valves, but by 4 months
th younger patients with mechanical valves had returned to
normal (demonstrating a lack of a correlation between HITS
and neuropsychologic outcome). In their 2006 article48 the
same group compared longer term (3 years) follow-up of
mechanical AVR with age-matched nonsurgical controls
and found no difference in neuropsychologic outcomes in
the valve recipients, although these studies can be criticized
for using only auditory-evoked P300 latencies as a neuro-
psychologic test.
Limitations
Although our study sought to determine the exact propor-
tion of solid and gaseous microemboli, its major limitation
is the lack of any associated cerebral outcome measure-
ments (eg, neurocognitive testing or magnetic resonance
imaging) and therefore uncertainty regarding the clinical
significance of its findings.
Because this was not a randomized trial, it is possible
that other differences between the 2 groups may have af-
fected the HITS rate independently of valve type. However,
as summarized in Tables 1 and 2, mechanical and biologi
valve recipients were well matched for the main factors
influencing the HITS rate, including myocardial contractil-
ity, heart rate, valve type and size, and method of valve
implantation. However, the results could also be affected by
the use of aspirin in the biologic valve group, which would
explain the reduction of microemboli detected over time in
group B but not in group M. Indeed, using aspirin instead of
warfarin after a biological aortic valve implantation is the
current practice among the majority of cardiac surgeons,
and consequently our findings reflect a “real-world”
situation.
Finally, because a number of different mechanical and
biologic valves were used in each group, we cannot com-rch 2008
Thorac Surg. 1999;68:1096-9.
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CDversus tilting disc for mechanical valves and stented versus
stentless for bioprostheses influenced the results.
Conclusions
Solid cerebral microemboli represent approximately one
third of the total cerebral microembolic load after mechan-
ical AVR and are detectable in the majority of such patients
both 5 days and 3 months after surgery.
The authors acknowledge Mr Ravi Pillai, Mr. Chandi Ratna-
tunga, and Mr Stephen Westaby for allowing us to study their
patients.
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